International application No. PCT/JP02/08809

	.cl <sup>1</sup> C07C237/06, 271/22, C07D2	07/20, 211/70, 295/20,	401/04,	
İ	401/06, 401/12, 405/12, 4			
31/40, 31/451, 31/4523, 31/453, 31/4535, 31/454, 31/4545, According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
	documentation searched (classification system followed C1 C07C237/06, 271/22, C07D2		401/04	
1110.	401/06, 401/12, 405/12, 4			
	31/40, 31/451, 31/4523, 3			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN (CA, REGISTRY)				
SIN	(CA, REGISTRI)			
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where a		Relevant to claim No.	
Х	EP 710661 A1 (Tobishi Pharma 08 May, 1996 (08.05.96),	aceutical Co., Ltd.),	1,3	
	Example 19 & JP 8-119940 A & US	S 5716958 A		
Х	US 4297346 A (Institut Nation Recherche Medicale),	nal de la Sante et de la	1,11-17,21	
	27 October, 1981 (27.10.81),			
	Table III & DE 2755036 A1 & GE	3 1592552 A		
	& DE 2733036 AI & GE	5 1392332 A		
х	R.S. KAMEL, J. LANDON, D.S. SM		1,2,5	
	Nortriptyline Derivatives and Phase or Magnetizable Solid-			
	Radioimmunoassays", Clinical			
	Vol.25, No.12, pages 1997 to 2002			
	NO.12, pages 155, to 2002			
X Further documents are listed in the continuation of Box C. See patent family annex.				
* Special categories of cited documents:  "A" document defining the general state of the art which is not		"T" later document published after the inte priority date and not in conflict with the		
conside	red to be of particular relevance document but published on or after the international filing	understand the principle or theory under "X" document of particular relevance; the	erlying the invention	
date	ent which may throw doubts on priority claim(s) or which is	considered novel or cannot be considered step when the document is taken alone	red to involve an inventive	
cited to establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the considered to involve an inventive step	when the document is	
means	ent referring to an oral disclosure, use, exhibition or other	combined with one or more other such combination being obvious to a person		
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent i	-	
		Date of mailing of the international search 19 November, 2002 (		
21 0	(21.10.02)	12 movemmet, 2002 (	17.11.02)	
Name and mailing address of the ISA/		Authorized officer		
Japanese Patent Office		•		
Facsimile No.		Telephone No.	.	

International application No. PCT/JP02/08809

- 10	DOCKINGNES CONSIDERED TO BE RELEVANT	
<del></del>	tion). DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passage	Relevant to claim No.
Category* A, P	WO 02/22588 Al (Ajinomoto Co., Inc.), 21 March, 2002 (21.03.02), Full text	1-23
A	& AU 2001-84504 A  WO 00/01375 Al (Neuromed Technologies, Inc.), 13 January, 2000 (13.01.00),	1-23
	Full text & JP 2002-519372 A & EP 1091737 A2	
A	WO 95/11238 Al (SmithKline Beecham Plc), 27 April, 1995 (27.04.95),	1-23
	Full text & EP 724577 A1	
	·	
		·
<b>i</b> .		

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

International application No.

PCT/JP02/08809

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. $\times$ Claims Nos.: 1, 2, 5, 11-13, 15-19, 21, and 22
because they relate to parts of the international application that do not comply with the prescribed requirements to such an
extent that no meaningful international search can be carried out, specifically: Claims 1, 2, 5, 11–13, 15–19, 21, and 22 are inadequately supported by the
description. Consequently, a relevant prior art technique cannot be
specified.
(to be continued on the last sheet)  3.
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers
only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
į
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

International application No. PCT/JP02/08809

Continuation of Box No. I-2 of continuation of

Claim 1 and other claims include compounds which are not specifically disclosed in the description and are considerably different in functional group, molecular structure, etc. from the compounds specifically disclosed in the description (for example, compounds in which both  $R^{11}$  and  $R^{12}$  are hydrogen and compounds in which A is  $NR^{17}CO$  wherein  $R^{17}$  is aryl; hereinafter, such compounds are referred to as "compounds lacking in disclosure, etc.").

However, the compounds capable of interacting with a receptor are generally limited to those having a specific functional group, specific size, and specific and structure hydrophilicity/hydrophobicity. In view of this, the compounds lacking in disclosure, etc. cannot be presumed to have the same antagonistic effect on N-type calcium channels as the compounds specifically disclosed in the description. The compounds lacking in disclosure, etc. cannot hence be considered to be adequately supported by the description.

Therefore, the compounds lacking in disclosure, etc. cannot be adequately judged as to whether a prior art technique has relevance to them (in particular, with respect to inventiveness).

An international search report was not made with respect to the following compounds and medicines containing any of these:

- a) compounds in which A is neither CH=CH, CH2CH2, S, CH2S, nor SCH2;
- b) compounds in which V-W is N-CH;
- c) compounds in which Z is N;
- d) compounds in which  $Y^1$ ,  $Y^3$ , and  $Y^4$  each is S;
- e) compounds in which G is SO or  $SO_2$ ; and f) compounds in which  $R^{11}$  and  $R^{12}$  each is neither formula (6) nor formula (7).

International application No.
PCT/JP02/08809

Continuation of A. CLASSIFICATION OF SUBJECT MATTER
(International Patent Classification (IPC))

Int.Cl<sup>7</sup> 31/495, 31/55, 38/05, A61P1/00, 9/00, 9/10, 11/00, 11/06, 25/00, 25/04, 25/06, 25/16, 25/28, 25/30, 43/00

(According to International Patent Classification (IPC) or to both national classification and IPC)

#### Continuation of B. FIELDS SEARCHED

Minimum Documentation Searched(International Patent Classification (IPC))

Int.Cl<sup>7</sup> 31/495, 31/55, 38/05, A61P1/00, 9/00, 9/10, 11/00, 11/06, 25/00, 25/04, 25/06, 25/16, 25/28, 25/30, 43/00

Minimum documentation searched (classification system followed by classification symbols)

Form PCT/ISA/210 (extra sheet) (July 1998)

# THIS PAGE BLANK (USPTO)